The Bloodline with Blood Cancer United Podcast cover art

The Bloodline with Blood Cancer United Podcast

The Bloodline with Blood Cancer United Podcast

By: Blood Cancer United
Listen for free

About this listen

 A Podcast for Patients and CaregiversThe Bloodline with LLS - Blood Cancer United Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives

    Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives
    Feb 26 2026
    CAR T‑cell therapy is redefining what personalized cancer treatment can look like, offering real promise for patients and families. In this episode, we speak with Dr. Richard Maziarz and CAR T Nurse Coordinator Bashi Ratterree of Oregon Health & Science University (OHSU). Together, they explain how CAR T‑cell therapy works, who may be eligible, what patients can expect during treatment and recovery, and the promising advancements shaping the future of this innovative therapy. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: CAR T-cell therapyClinical Trial Support CenterCAR T-Cell Therapy: A Path of Hope and Healing Video SeriesBloodline Breakthroughs: innovations and inspiration video podcast: CAR T-cell TherapyHematology Horizons vlog: CAR T-Cell Therapy and the Patient ExperienceCAR T-Cell Therapy: Side Effects video Additional Blood Cancer United Support Resources: Information Specialists Financial supportOnline ChatFree Nutrition ConsultationsFree telephone/web patient programs Free booklets Young Adult ResourcesSupport groups Caregiver support Caregiver WorkbookSurvivorship WorkbookAdvocacy and Public PolicyPatient CommunityMental Health Resources Episode supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; Kite, a Gilead Company; Novartis Pharmaceuticals Corporation. The post Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives first appeared on The Bloodline with Blood Cancer United Podcast.
    Show More Show Less
    49 mins
  • Cutaneous T-Cell Lymphoma (CTCL): Illuminating a Brighter Path Forward

    Cutaneous T-Cell Lymphoma (CTCL): Illuminating a Brighter Path Forward
    Feb 12 2026
    Stefan Barta, MD, MS

    Cutaneous T‑cell lymphoma (CTCL) is a rare condition that often raises important questions for patients and families.

    In this episode, we sit down with Dr. Stefan Barta, of the University of Pennsylvania, to bring clarity to what CTCL is, how it’s diagnosed, and what patients can expect from staging and treatment. Dr. Barta breaks down the differences between CTCL subtypes, explains why diagnosing someone can take time, and shares the most up-to-date therapies, including skin directed treatments, immunotherapies, and emerging clinical trial options. Most importantly, he offers reassurance for those newly diagnosed: “The future is absolutely bright… there is a lot of hope for our patients with CTCL.”

    DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey.

    Mentioned on this episode:

    • Cutaneous T-cell lymphoma
    • Cutaneous Lymphoma Foundation
    • Clinical Trial Support Center

    Additional Blood Cancer United Support Resources:

    • Free Nutrition Consultations
    • Information Specialists
    • Financial support
    • Online Chat
    • Free telephone/web patient programs
    • Free booklets
    • Young Adult Resources
    • Support groups
    • Caregiver support
    • Caregiver Workbook
    • Survivorship Workbook
    • Advocacy and Public Policy
    • Patient Community
    • Mental Health Resources

    Episode supported by Kyowa Kirin, Inc. and Cutaneous Lymphoma Foundation.

    The post Cutaneous T-Cell Lymphoma (CTCL): Illuminating a Brighter Path Forward first appeared on The Bloodline with Blood Cancer United Podcast.
    Show More Show Less
    38 mins
  • The Bloodline Live! Myelodysplastic Syndromes (MDS) Updates in Research

    The Bloodline Live! Myelodysplastic Syndromes (MDS) Updates in Research
    Jan 29 2026
    Mikkael A. Sekeres, MD, MS Curious about what’s new in the world of myelodysplastic syndromes (MDS)? We’re bringing you the latest insights straight from one of the field’s leading experts. In this episode, we speak with Dr. Mikkael Sekeres, of the Sylvester Comprehensive Cancer Center at University of Miami Health. Recorded onsite at the 2025 ASH (American Society of Hematology) Annual Meeting and Exposition, this conversation explores what MDS is, how it’s treated today, and what researchers are learning about managing side effects. Dr. Sekeres also walks us through the most notable MDS updates presented at ASH, highlighting promising therapies and clinical trial data that may help shape future care. Whether you’re newly learning about MDS or following ongoing research, this episode offers an accessible look at where things stand and what’s on the horizon. *This is not an official program of the ASH annual meeting DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Myelodysplastic syndromesInternational Prognostic Scoring System for MDSAmerican Society of HematologyHighlights from ASH vlogBlood cancer research 2026: Meeting patients where they want to be | blog post Additional Blood Cancer United Support Resources: Free Nutrition ConsultationsInformation Specialists Financial supportClinical Trial Support CenterOnline ChatFree telephone/web patient programs Free booklets Young Adult ResourcesSupport groups Caregiver support Caregiver WorkbookSurvivorship WorkbookAdvocacy and Public PolicyPatient CommunityMental Health Resources Episode supported by Geron Corporation and Taiho Oncology, Inc.The post The Bloodline Live! Myelodysplastic Syndromes (MDS) Updates in Research first appeared on The Bloodline with Blood Cancer United Podcast.
    Show More Show Less
    18 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.